Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 6.50 ($0.08) and last traded at GBX 6.40 ($0.08), with a volume of 91787 shares traded. The stock had previously closed at GBX 6.40 ($0.08).
Allergy Therapeutics Stock Performance
The firm’s 50 day moving average price is GBX 5.23 and its 200-day moving average price is GBX 4.96. The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The firm has a market capitalization of £305.28 million, a PE ratio of -106.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- 10 Best Airline Stocks to Buy
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
